NovaBay Pharmaceuticals to Hold 2017 First Quarter Conference Call on May 11, 2017
May 04 2017 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a
biopharmaceutical company focusing on commercializing its
prescription Avenova® lid and lash hygiene product for the domestic
eye care market, announces that it will report 2017 first quarter
financial results after market close on Thursday, May 11.
Management will hold an investment community conference call that
day to discuss financial results and provide a Company update.
DATE: Thursday, May 11 TIME: 4:30 p.m. ET /
1:30 p.m. PT DIAL IN: 800-608-8202 from within the U.S.
702-495-1913 from outside the U.S. Enter conference identification
number 14535369
The live call also will be available at
http://novabay.com/investors/events. A replay of the call will be
available beginning two hours after its completion through 12:59
p.m. Eastern time June 11, 2017, by dialing 855-859-2056 from
within the U.S. or 404-537-3406 from outside the U.S. and entering
the conference identification number 14535369. The call will also
be archived at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing
on the commercialization of prescription Avenova® lid and lash
hygiene for the eye care market. Avenova is formulated with
Neutrox®, which is cleared by the U.S. Food and Drug Administration
(FDA) as a 510(k) medical device. Neutrox is NovaBay’s pure
hypochlorous acid. Data from a multicenter clinical study show that
Avenova reduced bacterial load, the underlying cause of
blepharitis, on ocular skin surface by more than 90%. Laboratory
tests show that hypochlorous acid has potent antimicrobial activity
in solution yet is non-toxic to mammalian cells and also
neutralizes bacterial toxins. Avenova is marketed to optometrists
and ophthalmologists throughout the U.S. by NovaBay’s direct
medical salesforce. It is accessible from more than 90% of retail
pharmacies in the U.S. through agreements with McKesson
Corporation, Cardinal Health and AmerisourceBergen.
Stay informed on NovaBay's
progress:
Download our Mobile InvestorApp from the Apple
Store or Google PlayLike us on
FacebookFollow us on TwitterConnect with
NovaBay on LinkedInJoin us on
Google+Visit NovaBay's Website
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170504005008/en/
NovaBay ContactsFor NovaBay
Avenova purchasing information, please
contact:1-800-890-0329www.Avenova.comorFrom the CompanyThomas J. PaulsonChief
Financial Officer510-899-8809Contact TomorInvestor ContactLHAJody
Cain310-691-7100jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024